Vorapaxar (Zontivity) approved

CardioSource – FDA Approves Vorapaxar to Reduce Heart Attack and Stroke Risks in HighRisk Patients. The U.S. Food and Drug Administration (FDA) has approved vorapaxar (Zontivity) to reduce the risk for MI, stroke, cardiovascular-related death and coronary revascularization among patients who have previously experienced MI or peripheral artery disease. Vorapaxar is the first in a […]

%d bloggers like this: